Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study - Scorecard - MDSpire
Advertisement
Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study
Clinical Scorecard: Association of Vonoprazan with Increased Reporting of Cholangitis in Patients Treated with Immune Checkpoint Inhibitors: Insights from a VigiBase Pharmacovigilance Analysis
At a Glance
Category
Detail
Condition
Cholangitis
Key Mechanisms
Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) leading to hepatobiliary toxicity.
Target Population
Patients receiving immune checkpoint inhibitors for cancer treatment.
Care Setting
Pharmacovigilance analysis using VigiBase, the WHO global individual case safety report database.
Key Highlights
Immune checkpoint inhibitors can cause immune-related cholangitis, a severe hepatobiliary adverse event.
Vonoprazan, a potassium-competitive acid blocker, may have a distinct hepatobiliary safety profile compared to proton pump inhibitors.
The study utilized VigiBase to assess the association of vonoprazan with increased cholangitis reporting among ICI-treated patients.
Guideline-Based Recommendations
Diagnosis
Cholangitis is characterized by cholestatic liver injury and may require specific diagnostic criteria.
Management
Management of ICI-related cholangitis may be challenging and often refractory to corticosteroid therapy.
Monitoring & Follow-up
Patients receiving ICIs should be monitored for signs of cholangitis, especially when co-administered with vonoprazan.
Risks
Increased risk of cholangitis may limit the feasibility of ICI rechallenge.
Patient & Prescribing Data
Patients undergoing treatment with immune checkpoint inhibitors, particularly those also receiving acid-suppressive therapy.
The use of vonoprazan in this population may be associated with altered reporting patterns of cholangitis.
Clinical Best Practices
Consider the hepatobiliary safety profile of vonoprazan when prescribing for patients on ICIs.
Evaluate the necessity of acid suppression in patients receiving ICIs and monitor for hepatobiliary adverse events.
